---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-23-000145"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T16:24:28.728669+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Denali reports Q3 net loss $99.4M; cuts 2023 expense growth outlook to 15-20%

## Summary
- Net loss $99.4M (vs $103.3M); revenue $1.3M (vs $3.6M). Cash $1.12B.
- FY2023 cash op expense growth guidance reduced to 15-20% from prior 25-30%.
- Sanofi's eclitasertib failed CLE Phase 2; UC study continues. Biogen amended LRRK2 deal.
- Pipeline: DNL310 Phase 2/3 enrolling; DNL126 Phase 1/2 starting; OTV advancing 2 candidates to clinic.

## SEC filing metadata
- accession: 0001714899-23-000145
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000145/0001714899-23-000145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000145/dnli-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-23-000145
- JSON: https://secwatch.observer/filing/0001714899-23-000145.json
- Plain text: https://secwatch.observer/filing/0001714899-23-000145.txt

## Key facts
- Earnings Releases
  Denali Therapeutics Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 7, 2023, Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000145/0001714899-23-000145-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.